JP2018506981A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018506981A5 JP2018506981A5 JP2017544615A JP2017544615A JP2018506981A5 JP 2018506981 A5 JP2018506981 A5 JP 2018506981A5 JP 2017544615 A JP2017544615 A JP 2017544615A JP 2017544615 A JP2017544615 A JP 2017544615A JP 2018506981 A5 JP2018506981 A5 JP 2018506981A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- chain variable
- variable region
- cdrs
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 claims 12
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 11
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 210000004698 lymphocyte Anatomy 0.000 claims 7
- 239000013598 vector Substances 0.000 claims 6
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 102100036466 Delta-like protein 3 Human genes 0.000 claims 3
- 101000928513 Homo sapiens Delta-like protein 3 Proteins 0.000 claims 3
- 229940127276 delta-like ligand 3 Drugs 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000003834 intracellular effect Effects 0.000 claims 2
- 230000011664 signaling Effects 0.000 claims 2
- 230000002463 transducing effect Effects 0.000 claims 2
- 239000013603 viral vector Substances 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 201000002120 neuroendocrine carcinoma Diseases 0.000 claims 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 1
- 230000001177 retroviral effect Effects 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562119793P | 2015-02-23 | 2015-02-23 | |
| US62/119,793 | 2015-02-23 | ||
| US201562241662P | 2015-10-14 | 2015-10-14 | |
| US62/241,662 | 2015-10-14 | ||
| US201662296560P | 2016-02-17 | 2016-02-17 | |
| US62/296,560 | 2016-02-17 | ||
| PCT/US2016/019192 WO2016138038A1 (en) | 2015-02-23 | 2016-02-23 | Anti-dll3 chimeric antigen receptors and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018506981A JP2018506981A (ja) | 2018-03-15 |
| JP2018506981A5 true JP2018506981A5 (cg-RX-API-DMAC7.html) | 2019-04-04 |
Family
ID=56789774
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017544615A Pending JP2018506981A (ja) | 2015-02-23 | 2016-02-23 | 抗ｄｌｌ３キメラ抗原受容体および使用方法 |
Country Status (23)
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11385233B2 (en) | 2015-03-05 | 2022-07-12 | Autolus Limited | Methods of depleting malignant T-cells |
| US20230027993A1 (en) | 2014-03-05 | 2023-01-26 | Autolus Limited | Methods |
| GB201403972D0 (en) | 2014-03-06 | 2014-04-23 | Ucl Business Plc | Chimeric antigen receptor |
| SG10202002131PA (en) | 2015-05-21 | 2020-05-28 | Harpoon Therapeutics Inc | Trispecific binding proteins and methods of use |
| CN108395482B (zh) | 2017-02-08 | 2021-02-05 | 西比曼生物科技（香港）有限公司 | 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定 |
| CA3221995C (en) | 2017-02-08 | 2024-05-28 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| SG11201907646YA (en) | 2017-02-20 | 2019-09-27 | Dragonfly Therapeutics Inc | Proteins binding her2, nkg2d and cd16 |
| EP3655779A1 (en) | 2017-07-20 | 2020-05-27 | CytomX Therapeutics, Inc. | Methods of qualitatively and/or quantitatively analyzing properties of activatable antibodies and uses thereof |
| KR102172092B1 (ko) | 2017-09-19 | 2020-10-30 | 주식회사 엘지화학 | 열가소성 수지 조성물, 이의 제조방법 및 성형품 |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| EA202090817A1 (ru) | 2017-10-13 | 2020-09-08 | Харпун Терапьютикс, Инк. | Триспецифические белки и способы их применения |
| CN111247430A (zh) * | 2017-10-20 | 2020-06-05 | 南特生物科学公司 | 监测膀胱癌免疫疗法的方法 |
| PT3749346T (pt) | 2018-02-08 | 2024-09-05 | Dragonfly Therapeutics Inc | Combinações de domínios variáveis de anticorpos dirigidas ao receptor nkg2d |
| KR20200118824A (ko) | 2018-02-08 | 2020-10-16 | 드래곤플라이 쎄라퓨틱스, 인크. | 자연 살해 세포를 활성화시키는 다중-특이성 결합 단백질을 수반하는 암의 병용 요법 |
| US11110125B2 (en) * | 2018-02-13 | 2021-09-07 | Chimera Bioengineering, Inc. | Coordinating gene expression using RNA destabilizing elements |
| CA3091424A1 (en) | 2018-02-20 | 2019-08-29 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use |
| EP3774921A4 (en) * | 2018-04-03 | 2022-01-05 | Dragonfly Therapeutics, Inc. | ANTIBODY VARIABLE DOMAINS AGAINST DLL3 AND USE OF IT |
| KR20210018797A (ko) * | 2018-04-10 | 2021-02-18 | 암젠 인크 | Dll3에 대한 키메라 수용체 및 이의 사용 방법 |
| IL323061A (en) | 2018-04-11 | 2025-10-01 | Inhibrx Biosciences Inc | Multispecific polypeptide constructs with forced CD3 binding and related methods and uses |
| CN118146372A (zh) | 2018-05-08 | 2024-06-07 | 凡恩世制药(北京)有限公司 | 抗dll3抗体及其用途 |
| SG11202011330PA (en) | 2018-05-14 | 2020-12-30 | Harpoon Therapeutics Inc | Binding moiety for conditional activation of immunoglobulin molecules |
| WO2020023553A1 (en) | 2018-07-24 | 2020-01-30 | Inhibrx, Inc. | Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| CA3108646A1 (en) | 2018-08-08 | 2020-02-13 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and a tumor-associated antigen |
| AU2019318083A1 (en) | 2018-08-08 | 2021-02-25 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of use |
| EP3850088A4 (en) | 2018-09-07 | 2023-07-19 | Beam Therapeutics, Inc. | Compositions and methods for improving base editing |
| WO2020061482A1 (en) | 2018-09-21 | 2020-03-26 | Harpoon Therapeutics, Inc. | Egfr binding proteins and methods of use |
| CN113166263A (zh) * | 2018-10-11 | 2021-07-23 | 印希比股份有限公司 | Dll3单域抗体及其治疗性组合物 |
| EP3892333A4 (en) * | 2018-12-07 | 2022-11-30 | CRAGE medical Co., Limited | Tumor combined immunotherapy |
| CN113543799B (zh) * | 2019-03-01 | 2024-08-02 | 艾洛基治疗公司 | 靶向dll3的嵌合抗原受体和结合剂 |
| EP3908679A1 (en) * | 2019-03-08 | 2021-11-17 | OncoLab Diagnostics GmbH | Cancer diagnosis and prognosis |
| CN113795262A (zh) * | 2019-04-08 | 2021-12-14 | 东莞凡恩世生物医药有限公司 | 人源化抗dll3嵌合抗原受体及其用途 |
| CN114072427B (zh) * | 2019-07-17 | 2024-04-26 | 南京传奇生物科技有限公司 | 抗dll3嵌合抗原受体及其用途 |
| US20210046117A1 (en) * | 2019-08-18 | 2021-02-18 | Chimera Bioengineering, Inc. | Combination Therapy with Gold Controlled Transgenes |
| CN115643806A (zh) * | 2020-01-31 | 2023-01-24 | 璟尚生物制药公司 | 双特异性t细胞接合器 |
| US12486331B2 (en) | 2020-01-31 | 2025-12-02 | Gensun Biopharma Inc. | Bispecific T cell engagers |
| CN113402612A (zh) | 2020-03-17 | 2021-09-17 | 西比曼生物科技（香港）有限公司 | 靶向cd19和cd20的联合嵌合抗原受体及其应用 |
| CN113444173A (zh) * | 2020-03-25 | 2021-09-28 | 兴盟生物医药(苏州)有限公司 | 金黄色葡萄球菌α-毒素特异性抗体及其应用 |
| MX2022013944A (es) | 2020-05-06 | 2022-11-30 | Dragonfly Therapeutics Inc | Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a). |
| JP2024508894A (ja) | 2021-03-03 | 2024-02-28 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｎｋｇ２ｄ、ｃｄ１６、及び腫瘍関連抗原に結合する多特異性結合タンパク質を使用して癌を治療する方法 |
| EP4313081A4 (en) * | 2021-04-02 | 2025-04-09 | Nanjing Legend Biotech Co., Ltd. | MANIPULATED IMMUNE CELLS AND THEIR USES |
| CA3230627A1 (en) * | 2021-09-02 | 2023-03-09 | Memorial Sloan-Kettering Cancer Center | Antigen recognizing receptors targeting dll3 and uses thereof |
| EP4626447A1 (en) | 2023-03-31 | 2025-10-08 | AbelZeta Inc. | Bispecific chimeric antigen receptors targeting cd20 and bcma |
| CN117169518B (zh) * | 2023-11-03 | 2024-01-19 | 赛德特(北京)生物工程有限公司 | T淋巴细胞制剂中的cd3抗体残留物的检测方法和试剂盒 |
| WO2025212519A1 (en) * | 2024-04-01 | 2025-10-09 | Moonlight Bio, Inc. | Dll3 binding proteins and uses thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3342786T (lt) * | 2010-01-29 | 2021-10-25 | Chugai Seiyaku Kabushiki Kaisha | Anti-dll3 antikūnai |
| PH12013501201A1 (en) * | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| EP3095797B1 (en) * | 2012-02-24 | 2020-05-20 | AbbVie Stemcentrx LLC | Anti dll3 antibodies and methods of use thereof |
| KR20150037857A (ko) * | 2012-06-22 | 2015-04-08 | 싸이톰스 테라퓨틱스, 인크. | 항-jagged 1/jagged 2 교차-반응성 항체, 활성화가능한 항-jagged 항체 및 이의 제조 방법 |
| GB201302447D0 (en) * | 2013-02-12 | 2013-03-27 | Oxford Biotherapeutics Ltd | Therapeutic and diagnostic target |
| US9968687B2 (en) * | 2013-02-22 | 2018-05-15 | Abbvie Stemcentrx Llc | Anti-DLL3 antibody drug conjugates |
| WO2016179319A1 (en) * | 2015-05-04 | 2016-11-10 | Cellerant Therapeutics, Inc. | Chimeric antigen receptors with ctla4 signal transduction domains |
-
2016
- 2016-02-22 MA MA041613A patent/MA41613A/fr unknown
- 2016-02-23 MX MX2017010845A patent/MX2017010845A/es unknown
- 2016-02-23 KR KR1020177026963A patent/KR20170120158A/ko not_active Withdrawn
- 2016-02-23 EP EP16756219.8A patent/EP3261650A4/en not_active Withdrawn
- 2016-02-23 WO PCT/US2016/019192 patent/WO2016138038A1/en not_active Ceased
- 2016-02-23 US US15/553,102 patent/US20180044415A1/en not_active Abandoned
- 2016-02-23 JP JP2017544615A patent/JP2018506981A/ja active Pending
- 2016-02-23 EA EA201791884A patent/EA201791884A1/ru unknown
- 2016-02-23 TW TW105105289A patent/TW201639887A/zh unknown
- 2016-02-23 CN CN201680019227.8A patent/CN107405362A/zh active Pending
- 2016-02-23 SG SG11201706804SA patent/SG11201706804SA/en unknown
- 2016-02-23 BR BR112017017927A patent/BR112017017927A2/pt not_active IP Right Cessation
- 2016-02-23 CR CR20170436A patent/CR20170436A/es unknown
- 2016-02-23 PE PE2017001455A patent/PE20171383A1/es unknown
- 2016-02-23 HK HK18108019.0A patent/HK1249405A1/zh unknown
- 2016-02-23 CA CA2977502A patent/CA2977502A1/en not_active Abandoned
-
2017
- 2017-08-20 IL IL254068A patent/IL254068A0/en unknown
- 2017-08-22 ZA ZA2017/05720A patent/ZA201705720B/en unknown
- 2017-08-23 DO DO2017000199A patent/DOP2017000199A/es unknown
- 2017-08-23 PH PH12017501521A patent/PH12017501521A1/en unknown
- 2017-08-23 CL CL2017002150A patent/CL2017002150A1/es unknown
- 2017-08-29 CO CONC2017/0008804A patent/CO2017008804A2/es unknown
- 2017-09-22 EC ECIEPI201763327A patent/ECSP17063327A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018506981A5 (cg-RX-API-DMAC7.html) | ||
| JP7233425B2 (ja) | 細胞療法とガンマセクレターゼ阻害剤との組み合わせ | |
| Kleber et al. | BCMA in multiple myeloma—a promising key to therapy | |
| JP7299841B2 (ja) | 細胞療法と免疫調節化合物の併用 | |
| Bluhm et al. | CAR T cells with enhanced sensitivity to B cell maturation antigen for the targeting of B cell non-Hodgkin’s lymphoma and multiple myeloma | |
| KR102853341B1 (ko) | 조작된 ｔ 세포의 조성물을 제조하는 방법 | |
| RU2018111462A (ru) | Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток | |
| RU2016143381A (ru) | Способ и композиции для клеточной иммунотерапии | |
| JP2016534717A5 (cg-RX-API-DMAC7.html) | ||
| RU2018107802A (ru) | Полностью человеческие антитела к мезотелину и иммунные эффекторные клетки, нацеленные на мезотелин | |
| RU2018105963A (ru) | Антитело против глипикана-3 и его применение | |
| JP2020515259A5 (cg-RX-API-DMAC7.html) | ||
| RU2015109631A (ru) | Способ и композиции для клеточной иммунотерапии | |
| JP2017527275A5 (cg-RX-API-DMAC7.html) | ||
| JP2015513920A5 (cg-RX-API-DMAC7.html) | ||
| JP2018529327A5 (cg-RX-API-DMAC7.html) | ||
| FI4063397T3 (fi) | Yksidomeenivasta-aineisiin perustuvia antigeenireseptoreita ja menetelmiä niiden käyttämiseksi | |
| IL268620B2 (en) | Antibodies against LAG3 pharmaceutical formulations containing them, and their uses for cancer treatment | |
| JP2015508757A5 (cg-RX-API-DMAC7.html) | ||
| JP2019513347A5 (cg-RX-API-DMAC7.html) | ||
| JP2017513478A5 (cg-RX-API-DMAC7.html) | ||
| EP3491016A1 (en) | Combination therapies of chimeric antigen receptors and pd-1 inhibitors | |
| HRP20240926T1 (hr) | Claudin-6-specifični imunoreceptori i epitopi t stanica | |
| JP2018522564A5 (cg-RX-API-DMAC7.html) | ||
| RU2015117237A (ru) | Химерные антигенные рецепторы м971 |